Dr. David Harper, the Chief Scientific Officer of Biocontrol, gave an invited presentation entitled "Bacteriophages for the Treatment of Pseudomonas aeruginosa Infections". The presentation was included in the session on "Applied Bacteriophage Technology", and covered the particular suitability of this infection for control by bacteriophage therapeutics

Dr. David Harper, the Chief Scientific Officer of Biocontrol, gave an invited presentation entitled "The Role Of Regulated Clinical Trials In The Development Of Bacteriophage Therapeutics". The presentation was included in the session on Technological and Medical Applications", and focussed on the importance of high-quality trials in developing the field as a whole.

The Australian Patent Office has issued a Deed of Letters Patent for Australian patent 2004258731, which derived from Biocontrol’s 2004 patent filing “Bacteriophage-containing Therapeutic Agents” (WO 2005/009451 A1).

Notice of Allowance has been issued for US patent US2007190033 (A1), deriving from Biocontrol’s 2004 patent filing “Bacteriophage-containing Therapeutic Agents” (WO 2005/009451 A1).

Biocontrol Executive Chairman Dr. Caroline Williams presented information on the company and held discussions with potential partners at the Rodman Renshaw Healthcare Conference, May 16th to 18th at the Grosvenor House Hotel, London, UK.